Overview
About Arrow Dx
Arrow Dx is leveraging nanotechnology and AI to develop a low-cost, highly sensitive test for early detection of non-alcoholic fatty liver disease (NAFLD) which includes non-alcoholic steatohepatitis (NASH). Our technology platform addresses the lack of rapid, reliable, point-of-care diagnostics by enabling faster, portable, and affordable testing for use in epidemics, public health crises, emergency rooms, and the early diagnosis of complex non-communicable diseases.
Designed for accessibility, our compact, low-cost device empowers smaller providers—like Physician Office Labs (~250,000 in the U.S.), independent physicians, and public health workers—to deliver critical diagnostics. We are also developing tests for COVID-19 and other viruses, beginning with wastewater-based surveillance and expanding to individual biological sample detection.
Designed for accessibility, our compact, low-cost device empowers smaller providers—like Physician Office Labs (~250,000 in the U.S.), independent physicians, and public health workers—to deliver critical diagnostics. We are also developing tests for COVID-19 and other viruses, beginning with wastewater-based surveillance and expanding to individual biological sample detection.